Skip to main content
Top
Published in: Health and Quality of Life Outcomes 1/2007

Open Access 01-12-2007 | Research

Validation of two generic patient-reported outcome measures in patients with type 2 diabetes

Authors: Louis S Matza, Kristina S Boye, Nicole Yurgin

Published in: Health and Quality of Life Outcomes | Issue 1/2007

Login to get access

Abstract

Background

Prior to using a generic patient-reported outcome measure (PRO), the measure should be validated within the target population. The purpose of the current study was to validate two generic measures in patients with type 2 diabetes.

Methods

Patients with type 2 diabetes in Scotland and England completed two generic measures: EQ-5D and Psychological General Well-Being Index (PGWB). Two diabetes-specific measures were administered: ADS and DSC-R. Analyses assessed reliability and validity.

Results

There were 130 participants (53 Scotland; 77 England; 64% male; mean age = 55.7 years). Responses on the EQ-5D and PGWB reflected moderate impairment consistent with previous diabetes samples: mean EQ-5D Index score, 0.75; EQ-5D VAS, 68.8; PGWB global score, 67.9. All scales of the PGWB demonstrated good internal consistency reliability (Cronbach's alpha = 0.77 to 0.97). The EQ-5D and PGWB demonstrated convergent validity through significant correlations with the ADS (r = 0.48 to 0.61), DSC-R scales (r = 0.33 to 0.81 except ophthalmology subscale), and Body Mass Index (r = 0.15 to 0.38). The EQ-5D and PGWB discriminated between groups of patients known to differ in diabetes-related characteristics (e.g., history of hypoglycemia).

Conclusion

Results support the use of the EQ-5D and PGWB among patients with type 2 diabetes, possibly in combination with condition-specific measures.
Literature
1.
go back to reference Coons SJ, Rao S, Keininger DL, Hays RD: A comparative review of generic quality-of-life instruments. Pharmacoeconomics 2000, 17: 13–35. 10.2165/00019053-200017010-00002PubMedCrossRef Coons SJ, Rao S, Keininger DL, Hays RD: A comparative review of generic quality-of-life instruments. Pharmacoeconomics 2000, 17: 13–35. 10.2165/00019053-200017010-00002PubMedCrossRef
2.
go back to reference Guyatt GH, Feeny DH, Patrick DL: Measuring health-related quality of life. Ann Intern Med 1993, 118: 622–629.PubMedCrossRef Guyatt GH, Feeny DH, Patrick DL: Measuring health-related quality of life. Ann Intern Med 1993, 118: 622–629.PubMedCrossRef
3.
go back to reference Patrick DL, Deyo RA: Generic and disease-specific measures in assessing health status and quality of life. Med Care 1989, 27: S217–32. 10.1097/00005650-198903001-00018PubMedCrossRef Patrick DL, Deyo RA: Generic and disease-specific measures in assessing health status and quality of life. Med Care 1989, 27: S217–32. 10.1097/00005650-198903001-00018PubMedCrossRef
4.
go back to reference Kalpaklioglu AF, Kara T, Kurtipek E, Kocyigit P, Ekici A, Ekici M: Evaluation and impact of chronic cough: comparison of specific vs generic quality-of-life questionnaires. Ann Allergy Asthma Immunol 2005, 94: 581–585.PubMedCrossRef Kalpaklioglu AF, Kara T, Kurtipek E, Kocyigit P, Ekici A, Ekici M: Evaluation and impact of chronic cough: comparison of specific vs generic quality-of-life questionnaires. Ann Allergy Asthma Immunol 2005, 94: 581–585.PubMedCrossRef
5.
go back to reference Leong KP, Yeak SC, Saurajen AS, Mok PK, Earnest A, Siow JK, Chee NW, Yeo SB, Khoo ML, Lee JC, Seshadri R, Chan SP, Tang CY, Chng HH: Why generic and disease-specific quality-of-life instruments should be used together for the evaluation of patients with persistent allergic rhinitis. Clin Exp Allergy 2005, 35: 288–298. 10.1111/j.1365-2222.2005.02201.xPubMedCrossRef Leong KP, Yeak SC, Saurajen AS, Mok PK, Earnest A, Siow JK, Chee NW, Yeo SB, Khoo ML, Lee JC, Seshadri R, Chan SP, Tang CY, Chng HH: Why generic and disease-specific quality-of-life instruments should be used together for the evaluation of patients with persistent allergic rhinitis. Clin Exp Allergy 2005, 35: 288–298. 10.1111/j.1365-2222.2005.02201.xPubMedCrossRef
6.
go back to reference Wiebe S, Guyatt G, Weaver B, Matijevic S, Sidwell C: Comparative responsiveness of generic and specific quality-of-life instruments. J Clin Epidemiol 2003, 56: 52–60. 10.1016/S0895-4356(02)00537-1PubMedCrossRef Wiebe S, Guyatt G, Weaver B, Matijevic S, Sidwell C: Comparative responsiveness of generic and specific quality-of-life instruments. J Clin Epidemiol 2003, 56: 52–60. 10.1016/S0895-4356(02)00537-1PubMedCrossRef
7.
go back to reference Guyatt GH, King DR, Feeny DH, Stubbing D, Goldstein RS: Generic and specific measurement of health-related quality of life in a clinical trial of respiratory rehabilitation. J Clin Epidemiol 1999, 52: 187–192. 10.1016/S0895-4356(98)00157-7PubMedCrossRef Guyatt GH, King DR, Feeny DH, Stubbing D, Goldstein RS: Generic and specific measurement of health-related quality of life in a clinical trial of respiratory rehabilitation. J Clin Epidemiol 1999, 52: 187–192. 10.1016/S0895-4356(98)00157-7PubMedCrossRef
8.
go back to reference Graue M, Wentzel-Larsen T, Hanestad BR, Batsvik B, Sovik O: Measuring self-reported, health-related, quality of life in adolescents with type 1 diabetes using both generic and disease-specific instruments. Acta Paediatr 2003, 92: 1190–1196. 10.1080/08035250310005657PubMedCrossRef Graue M, Wentzel-Larsen T, Hanestad BR, Batsvik B, Sovik O: Measuring self-reported, health-related, quality of life in adolescents with type 1 diabetes using both generic and disease-specific instruments. Acta Paediatr 2003, 92: 1190–1196. 10.1080/08035250310005657PubMedCrossRef
9.
go back to reference Leidy NK, Revicki DA, Geneste B: Recommendations for evaluating the validity of quality of life claims for labeling and promotion. Value in Health 1999, 2: 113–127. 10.1046/j.1524-4733.1999.02210.xPubMedCrossRef Leidy NK, Revicki DA, Geneste B: Recommendations for evaluating the validity of quality of life claims for labeling and promotion. Value in Health 1999, 2: 113–127. 10.1046/j.1524-4733.1999.02210.xPubMedCrossRef
10.
go back to reference Kosinski M, Zhao SZ, Dedhiya S, Osterhaus JT, Ware JE Jr.: Determining minimally important changes in generic and disease-specific health-related quality of life questionnaires in clinical trials of rheumatoid arthritis. Arthritis Rheum 2000, 43: 1478–1487. 10.1002/1529-0131(200007)43:7<1478::AID-ANR10>3.0.CO;2-MPubMedCrossRef Kosinski M, Zhao SZ, Dedhiya S, Osterhaus JT, Ware JE Jr.: Determining minimally important changes in generic and disease-specific health-related quality of life questionnaires in clinical trials of rheumatoid arthritis. Arthritis Rheum 2000, 43: 1478–1487. 10.1002/1529-0131(200007)43:7<1478::AID-ANR10>3.0.CO;2-MPubMedCrossRef
11.
go back to reference Schrag A, Selai C, Jahanshahi M, Quinn NP: The EQ-5D--a generic quality of life measure-is a useful instrument to measure quality of life in patients with Parkinson's disease. J Neurol Neurosurg Psychiatry 2000, 69: 67–73. 10.1136/jnnp.69.1.67PubMedCentralPubMedCrossRef Schrag A, Selai C, Jahanshahi M, Quinn NP: The EQ-5D--a generic quality of life measure-is a useful instrument to measure quality of life in patients with Parkinson's disease. J Neurol Neurosurg Psychiatry 2000, 69: 67–73. 10.1136/jnnp.69.1.67PubMedCentralPubMedCrossRef
12.
go back to reference Brennan DS, Spencer AJ: Comparison of a generic and a specific measure of oral health related quality of life. Community Dental Health 2004,22(1):11–18. Brennan DS, Spencer AJ: Comparison of a generic and a specific measure of oral health related quality of life. Community Dental Health 2004,22(1):11–18.
13.
go back to reference Iglesias CP, Birks Y, Nelson EA, Scanlon E, Cullum NA: Quality of life of people with venous leg ulcers: a comparison of the discriminative and responsive characteristics of two generic and a disease specific instruments. Qual Life Res 2005, 14: 1705–1718. 10.1007/s11136-005-2751-9PubMedCrossRef Iglesias CP, Birks Y, Nelson EA, Scanlon E, Cullum NA: Quality of life of people with venous leg ulcers: a comparison of the discriminative and responsive characteristics of two generic and a disease specific instruments. Qual Life Res 2005, 14: 1705–1718. 10.1007/s11136-005-2751-9PubMedCrossRef
14.
go back to reference Katsura H, Yamada K, Kida K: Both generic and disease specific health-related quality of life are deteriorated in patients with underweight COPD. Respir Med 2005, 99: 624–630. 10.1016/j.rmed.2004.09.017PubMedCrossRef Katsura H, Yamada K, Kida K: Both generic and disease specific health-related quality of life are deteriorated in patients with underweight COPD. Respir Med 2005, 99: 624–630. 10.1016/j.rmed.2004.09.017PubMedCrossRef
15.
go back to reference Michalak EE, Tam EM, Manjunath CV, Solomons K, Levitt AJ, Levitan R, Enns M, Morehouse R, Yatham LN, Lam RW: Generic and health-related quality of life in patients with seasonal and nonseasonal depression. Psychiatry Res 2004, 128: 245–251. 10.1016/j.psychres.2004.01.012PubMedCrossRef Michalak EE, Tam EM, Manjunath CV, Solomons K, Levitt AJ, Levitan R, Enns M, Morehouse R, Yatham LN, Lam RW: Generic and health-related quality of life in patients with seasonal and nonseasonal depression. Psychiatry Res 2004, 128: 245–251. 10.1016/j.psychres.2004.01.012PubMedCrossRef
16.
go back to reference Yilmaz B, Goktepe AS, Alaca R, Mohur H, Kayar AH: Comparison of a generic and a disease specific quality of life scale to assess a comprehensive spa therapy program for knee osteoarthritis. Joint Bone Spine 2004, 71: 563–566. 10.1016/j.jbspin.2003.09.008PubMedCrossRef Yilmaz B, Goktepe AS, Alaca R, Mohur H, Kayar AH: Comparison of a generic and a disease specific quality of life scale to assess a comprehensive spa therapy program for knee osteoarthritis. Joint Bone Spine 2004, 71: 563–566. 10.1016/j.jbspin.2003.09.008PubMedCrossRef
17.
go back to reference Engstrom CP, Persson LO, Larsson S, Sullivan M: Health-related quality of life in COPD: why both disease-specific and generic measures should be used. Eur Respir J 2001, 18: 69–76. 10.1183/09031936.01.00044901PubMedCrossRef Engstrom CP, Persson LO, Larsson S, Sullivan M: Health-related quality of life in COPD: why both disease-specific and generic measures should be used. Eur Respir J 2001, 18: 69–76. 10.1183/09031936.01.00044901PubMedCrossRef
18.
go back to reference Brommels M, Sintonen H: Be generic and specific: quality of life measurement in clinical studies. Ann Med 2001, 33: 319–322.PubMedCrossRef Brommels M, Sintonen H: Be generic and specific: quality of life measurement in clinical studies. Ann Med 2001, 33: 319–322.PubMedCrossRef
19.
go back to reference Vickrey BG, Hays RD, Genovese BJ, Myers LW, Ellison GW: Comparison of a generic to disease-targeted health-related quality-of-life measures for multiple sclerosis. J Clin Epidemiol 1997, 50: 557–569. 10.1016/S0895-4356(97)00001-2PubMedCrossRef Vickrey BG, Hays RD, Genovese BJ, Myers LW, Ellison GW: Comparison of a generic to disease-targeted health-related quality-of-life measures for multiple sclerosis. J Clin Epidemiol 1997, 50: 557–569. 10.1016/S0895-4356(97)00001-2PubMedCrossRef
20.
go back to reference de Lusignan S, Sismanidis C, Carey IM, DeWilde S, Richards N, Cook DG: Trends in the prevalence and management of diagnosed type 2 diabetes 1994–2001 in England and Wales. BMC Fam Pract 2005, 6: 13. 10.1186/1471-2296-6-13PubMedCentralCrossRef de Lusignan S, Sismanidis C, Carey IM, DeWilde S, Richards N, Cook DG: Trends in the prevalence and management of diagnosed type 2 diabetes 1994–2001 in England and Wales. BMC Fam Pract 2005, 6: 13. 10.1186/1471-2296-6-13PubMedCentralCrossRef
21.
go back to reference Dunstan DW, Zimmet PZ, Welborn TA, De Courten MP, Cameron AJ, Sicree RA, Dwyer T, Colagiuri S, Jolley D, Knuiman M, Atkins R, Shaw JE: The rising prevalence of diabetes and impaired glucose tolerance: the Australian Diabetes, Obesity and Lifestyle Study. Diabetes Care 2002, 25: 829–834. 10.2337/diacare.25.5.829PubMedCrossRef Dunstan DW, Zimmet PZ, Welborn TA, De Courten MP, Cameron AJ, Sicree RA, Dwyer T, Colagiuri S, Jolley D, Knuiman M, Atkins R, Shaw JE: The rising prevalence of diabetes and impaired glucose tolerance: the Australian Diabetes, Obesity and Lifestyle Study. Diabetes Care 2002, 25: 829–834. 10.2337/diacare.25.5.829PubMedCrossRef
22.
go back to reference Glasgow RE, Ruggiero L, Eakin EG, Dryfoos J, Chobanian L: Quality of life and associated characteristics in a large national sample of adults with diabetes. Diabetes Care 1997, 20: 562–567. 10.2337/diacare.20.4.562PubMedCrossRef Glasgow RE, Ruggiero L, Eakin EG, Dryfoos J, Chobanian L: Quality of life and associated characteristics in a large national sample of adults with diabetes. Diabetes Care 1997, 20: 562–567. 10.2337/diacare.20.4.562PubMedCrossRef
23.
go back to reference Hanninen J, Takala J, Keinanen-Kiukaanniemi S: Quality of life in NIDDM patients assessed with the SF-20 questionnaire. Diabetes Res Clin Pract 1998, 42: 17–27. 10.1016/S0168-8227(98)00085-0PubMedCrossRef Hanninen J, Takala J, Keinanen-Kiukaanniemi S: Quality of life in NIDDM patients assessed with the SF-20 questionnaire. Diabetes Res Clin Pract 1998, 42: 17–27. 10.1016/S0168-8227(98)00085-0PubMedCrossRef
24.
go back to reference King H, Aubert RE, Herman WH: Global burden of diabetes, 1995–2025: prevalence, numerical estimates, and projections. Diabetes Care 1998, 21: 1414–1431. 10.2337/diacare.21.9.1414PubMedCrossRef King H, Aubert RE, Herman WH: Global burden of diabetes, 1995–2025: prevalence, numerical estimates, and projections. Diabetes Care 1998, 21: 1414–1431. 10.2337/diacare.21.9.1414PubMedCrossRef
25.
go back to reference Lloyd A, Sawyer W, Hopkinson P: Impact of long-term complications on quality of life in patients with type 2 diabetes not using insulin. Value Health 2001, 4: 392–400. 10.1046/j.1524-4733.2001.45029.xPubMedCrossRef Lloyd A, Sawyer W, Hopkinson P: Impact of long-term complications on quality of life in patients with type 2 diabetes not using insulin. Value Health 2001, 4: 392–400. 10.1046/j.1524-4733.2001.45029.xPubMedCrossRef
26.
go back to reference Mokdad AH, Ford ES, Bowman BA, Dietz WH, Vinicor F, Bales VS, Marks JS: Prevalence of obesity, diabetes, and obesity-related health risk factors, 2001. JAMA 2003, 289: 76–79. 10.1001/jama.289.1.76PubMedCrossRef Mokdad AH, Ford ES, Bowman BA, Dietz WH, Vinicor F, Bales VS, Marks JS: Prevalence of obesity, diabetes, and obesity-related health risk factors, 2001. JAMA 2003, 289: 76–79. 10.1001/jama.289.1.76PubMedCrossRef
27.
go back to reference Varughese GI, Tomson J, Lip GY: Type 2 diabetes mellitus: a cardiovascular perspective. Int J Clin Pract 2005, 59: 798–816. 10.1111/j.1368-5031.2005.00571.xPubMedCrossRef Varughese GI, Tomson J, Lip GY: Type 2 diabetes mellitus: a cardiovascular perspective. Int J Clin Pract 2005, 59: 798–816. 10.1111/j.1368-5031.2005.00571.xPubMedCrossRef
28.
go back to reference Brooks R, Rabin R, de Charro F: The Measurement and Valuation of Health Status using EQ-5D: A European Perspective. Dordrecht, Kluwer Academic Publishers; 2003.CrossRef Brooks R, Rabin R, de Charro F: The Measurement and Valuation of Health Status using EQ-5D: A European Perspective. Dordrecht, Kluwer Academic Publishers; 2003.CrossRef
29.
go back to reference EuroQol Group: EuroQol--a new facility for the measurement of health-related quality of life. Health Policy 1990, 16: 199–208. 10.1016/0168-8510(90)90421-9CrossRef EuroQol Group: EuroQol--a new facility for the measurement of health-related quality of life. Health Policy 1990, 16: 199–208. 10.1016/0168-8510(90)90421-9CrossRef
30.
go back to reference Bagust A, Beale S: Modelling EuroQol health-related utility values for diabetic complications from CODE-2 data. Health Econ 2005, 14: 217–230. 10.1002/hec.910PubMedCrossRef Bagust A, Beale S: Modelling EuroQol health-related utility values for diabetic complications from CODE-2 data. Health Econ 2005, 14: 217–230. 10.1002/hec.910PubMedCrossRef
31.
go back to reference Clarke P, Gray A, Holman R: Estimating utility values for health states of type 2 diabetic patients using the EQ-5D (UKPDS 62). Med Decis Making 2002, 22: 340–349. 10.1177/027298902400448902PubMedCrossRef Clarke P, Gray A, Holman R: Estimating utility values for health states of type 2 diabetic patients using the EQ-5D (UKPDS 62). Med Decis Making 2002, 22: 340–349. 10.1177/027298902400448902PubMedCrossRef
32.
go back to reference Koopmanschap M: Coping with Type II diabetes: the patient's perspective. Diabetologia 2002, 45: S18–22.PubMedCrossRef Koopmanschap M: Coping with Type II diabetes: the patient's perspective. Diabetologia 2002, 45: S18–22.PubMedCrossRef
33.
go back to reference Lee AJ, Morgan CL, Morrissey M, Wittrup-Jensen KU, Kennedy-Martin T, Currie CJ: Evaluation of the association between the EQ-5D (health-related utility) and body mass index (obesity) in hospital-treated people with Type 1 diabetes, Type 2 diabetes and with no diagnosed diabetes. Diabet Med 2005, 22: 1482–1486. 10.1111/j.1464-5491.2005.01657.xPubMedCrossRef Lee AJ, Morgan CL, Morrissey M, Wittrup-Jensen KU, Kennedy-Martin T, Currie CJ: Evaluation of the association between the EQ-5D (health-related utility) and body mass index (obesity) in hospital-treated people with Type 1 diabetes, Type 2 diabetes and with no diagnosed diabetes. Diabet Med 2005, 22: 1482–1486. 10.1111/j.1464-5491.2005.01657.xPubMedCrossRef
34.
go back to reference Redekop WK, Koopmanschap MA, Stolk RP, Rutten GE, Wolffenbuttel BH, Niessen LW: Health-related quality of life and treatment satisfaction in Dutch patients with type 2 diabetes. Diabetes Care 2002, 25: 458–463. 10.2337/diacare.25.3.458PubMedCrossRef Redekop WK, Koopmanschap MA, Stolk RP, Rutten GE, Wolffenbuttel BH, Niessen LW: Health-related quality of life and treatment satisfaction in Dutch patients with type 2 diabetes. Diabetes Care 2002, 25: 458–463. 10.2337/diacare.25.3.458PubMedCrossRef
35.
go back to reference UK Prospective Diabetes Study Group (UKPDS): Quality of life in type 2 diabetic patients is affected by complications but not by intensive policies to improve blood glucose or blood pressure control (UKPDS 37). Diabetes Care 1999, 22: 1125–1136. 10.2337/diacare.22.7.1125CrossRef UK Prospective Diabetes Study Group (UKPDS): Quality of life in type 2 diabetic patients is affected by complications but not by intensive policies to improve blood glucose or blood pressure control (UKPDS 37). Diabetes Care 1999, 22: 1125–1136. 10.2337/diacare.22.7.1125CrossRef
36.
go back to reference Dupuy HJ: The Psychological General Well-Being (PGWB) Index. In Assessment of Quality of Life in Clinical Trials of Cardiovascular Therapies. Edited by: Wenger, N. K., Mattson, M. E., Furberg, C. D. and et al.. Washington, DC, Le Jacq Publishing; 1984:170–183. Dupuy HJ: The Psychological General Well-Being (PGWB) Index. In Assessment of Quality of Life in Clinical Trials of Cardiovascular Therapies. Edited by: Wenger, N. K., Mattson, M. E., Furberg, C. D. and et al.. Washington, DC, Le Jacq Publishing; 1984:170–183.
37.
go back to reference Herlitz J, Caidahl K, Wiklund I, Sjoland H, Karlson BW, Karlsson T, Haglid M, Hartford M: Impact of a history of diabetes on the improvement of symptoms and quality of life during 5 years after coronary artery bypass grafting. J Diabetes Complications 2000, 14: 314–321. 10.1016/S1056-8727(00)00115-XPubMedCrossRef Herlitz J, Caidahl K, Wiklund I, Sjoland H, Karlson BW, Karlsson T, Haglid M, Hartford M: Impact of a history of diabetes on the improvement of symptoms and quality of life during 5 years after coronary artery bypass grafting. J Diabetes Complications 2000, 14: 314–321. 10.1016/S1056-8727(00)00115-XPubMedCrossRef
38.
go back to reference Shobhana R, Rama Rao P, Lavanya A, Padma C, Vijay V, Ramachandran A: Quality of life and diabetes integration among subjects with type 2 diabetes. J Assoc Physicians India 2003, 51: 363–365.PubMed Shobhana R, Rama Rao P, Lavanya A, Padma C, Vijay V, Ramachandran A: Quality of life and diabetes integration among subjects with type 2 diabetes. J Assoc Physicians India 2003, 51: 363–365.PubMed
39.
go back to reference Leonardson GR, Daniels MC, Ness FK, Kemper E, Mihura JL, Koplin BA, Foreyt JP: Validity and reliability of the general well-being schedule with northern plains American Indians diagnosed with type 2 diabetes mellitus. Psychol Rep 2003, 93: 49–58. 10.2466/PR0.93.5.49-58PubMedCrossRef Leonardson GR, Daniels MC, Ness FK, Kemper E, Mihura JL, Koplin BA, Foreyt JP: Validity and reliability of the general well-being schedule with northern plains American Indians diagnosed with type 2 diabetes mellitus. Psychol Rep 2003, 93: 49–58. 10.2466/PR0.93.5.49-58PubMedCrossRef
40.
go back to reference Krabbe P, Weijnen T: Guidelines for analysing and reporting EQ-5D outcomes. In The Measurement and Valuation of Health Status using EQ-5D: A European Perspective. Edited by: Brooks R, Rabin R and de Charro F. Dordrecht, Kluwer Academic Publishers; 2003. Krabbe P, Weijnen T: Guidelines for analysing and reporting EQ-5D outcomes. In The Measurement and Valuation of Health Status using EQ-5D: A European Perspective. Edited by: Brooks R, Rabin R and de Charro F. Dordrecht, Kluwer Academic Publishers; 2003.
41.
go back to reference McDowell I, Newell C: Measuring Health: A guide to rating scales and questionnaires. 2nd edition. New York, Oxford University Press; 1996. McDowell I, Newell C: Measuring Health: A guide to rating scales and questionnaires. 2nd edition. New York, Oxford University Press; 1996.
42.
go back to reference Chassany O, Dimenas E, Dubois D, Wu A: PGWBI User Manual. Lyon, France, MAPI Research Institute; 2004. Chassany O, Dimenas E, Dubois D, Wu A: PGWBI User Manual. Lyon, France, MAPI Research Institute; 2004.
43.
go back to reference Carey MP, Jorgensen RS, Weinstock RS, Sprafkin RP, Lantinga LJ, Carnrike CL Jr., Baker MT, Meisler AW: Reliability and validity of the appraisal of diabetes scale. J Behav Med 1991, 14: 43–51. 10.1007/BF00844767PubMedCrossRef Carey MP, Jorgensen RS, Weinstock RS, Sprafkin RP, Lantinga LJ, Carnrike CL Jr., Baker MT, Meisler AW: Reliability and validity of the appraisal of diabetes scale. J Behav Med 1991, 14: 43–51. 10.1007/BF00844767PubMedCrossRef
44.
go back to reference Grootenhuis PA, Snoek FJ, Heine RJ, Bouter LM: Development of a type 2 diabetes symptom checklist: a measure of symptom severity. Diabet Med 1994, 11: 253–261.PubMedCrossRef Grootenhuis PA, Snoek FJ, Heine RJ, Bouter LM: Development of a type 2 diabetes symptom checklist: a measure of symptom severity. Diabet Med 1994, 11: 253–261.PubMedCrossRef
45.
go back to reference Garrow JS, Webster J: Quetelet's index (W/H2) as a measure of fatness. Int J Obes 1985, 9: 147–153.PubMed Garrow JS, Webster J: Quetelet's index (W/H2) as a measure of fatness. Int J Obes 1985, 9: 147–153.PubMed
46.
go back to reference Centers for Disease Control and Prevention (CDC): Prevalence of overweight and obesity among adults with diagnosed diabetes--United States, 1988–1994 and 1999–2002. MMWR Morb Mortal Wkly Rep 2004, 53: 1066–1068. Centers for Disease Control and Prevention (CDC): Prevalence of overweight and obesity among adults with diagnosed diabetes--United States, 1988–1994 and 1999–2002. MMWR Morb Mortal Wkly Rep 2004, 53: 1066–1068.
47.
48.
go back to reference Bulpitt CJ, Palmer AJ, Battersby C, Fletcher AE: Association of symptoms of type 2 diabetic patients with severity of disease, obesity, and blood pressure. Diabetes Care 1998, 21: 111–115. 10.2337/diacare.21.1.111PubMedCrossRef Bulpitt CJ, Palmer AJ, Battersby C, Fletcher AE: Association of symptoms of type 2 diabetic patients with severity of disease, obesity, and blood pressure. Diabetes Care 1998, 21: 111–115. 10.2337/diacare.21.1.111PubMedCrossRef
49.
go back to reference Maggio CA, Pi-Sunyer FX: The prevention and treatment of obesity. Application to type 2 diabetes. Diabetes Care 1997, 20: 1744–1766.PubMedCrossRef Maggio CA, Pi-Sunyer FX: The prevention and treatment of obesity. Application to type 2 diabetes. Diabetes Care 1997, 20: 1744–1766.PubMedCrossRef
50.
go back to reference Scheen AJ: Treatment of diabetes in patients with severe obesity. Biomed Pharmacother 2000, 54: 74–79. 10.1016/S0753-3322(00)88855-1PubMedCrossRef Scheen AJ: Treatment of diabetes in patients with severe obesity. Biomed Pharmacother 2000, 54: 74–79. 10.1016/S0753-3322(00)88855-1PubMedCrossRef
51.
go back to reference Cohen J: Statistical Power Analysis for the Behavioral Sciences. 2nd edition. Hillsdale, NJ, Lawrence Erlbaum Associates; 1988. Cohen J: Statistical Power Analysis for the Behavioral Sciences. 2nd edition. Hillsdale, NJ, Lawrence Erlbaum Associates; 1988.
52.
go back to reference Sullivan PW, Morrato EH, Ghushchyan V, Wyatt HR, Hill JO: Obesity, inactivity, and the prevalence of diabetes and diabetes-related cardiovascular comorbidities in the U.S., 2000–2002. Diabetes Care 2005, 28: 1599–1603. 10.2337/diacare.28.7.1599PubMedCrossRef Sullivan PW, Morrato EH, Ghushchyan V, Wyatt HR, Hill JO: Obesity, inactivity, and the prevalence of diabetes and diabetes-related cardiovascular comorbidities in the U.S., 2000–2002. Diabetes Care 2005, 28: 1599–1603. 10.2337/diacare.28.7.1599PubMedCrossRef
53.
go back to reference Garratt AM, Schmidt L, Fitzpatrick R: Patient-assessed health outcome measures for diabetes: a structured review. Diabet Med 2002, 19: 1–11. 10.1046/j.1464-5491.2002.00650.xPubMedCrossRef Garratt AM, Schmidt L, Fitzpatrick R: Patient-assessed health outcome measures for diabetes: a structured review. Diabet Med 2002, 19: 1–11. 10.1046/j.1464-5491.2002.00650.xPubMedCrossRef
54.
go back to reference Luscombe FA: Health-related quality of life measurement in type 2 diabetes. Value Health 2000, 3 Suppl 1: 15–28. 10.1046/j.1524-4733.2000.36032.xPubMedCrossRef Luscombe FA: Health-related quality of life measurement in type 2 diabetes. Value Health 2000, 3 Suppl 1: 15–28. 10.1046/j.1524-4733.2000.36032.xPubMedCrossRef
55.
go back to reference Revicki DA, Osoba D, Fairclough D, Barofsky I, Berzon R, Leidy NK, Rothman M: Recommendations on health-related quality of life research to support labeling and promotional claims in the United States. Qual Life Res 2000, 9: 887–900. 10.1023/A:1008996223999PubMedCrossRef Revicki DA, Osoba D, Fairclough D, Barofsky I, Berzon R, Leidy NK, Rothman M: Recommendations on health-related quality of life research to support labeling and promotional claims in the United States. Qual Life Res 2000, 9: 887–900. 10.1023/A:1008996223999PubMedCrossRef
Metadata
Title
Validation of two generic patient-reported outcome measures in patients with type 2 diabetes
Authors
Louis S Matza
Kristina S Boye
Nicole Yurgin
Publication date
01-12-2007
Publisher
BioMed Central
Published in
Health and Quality of Life Outcomes / Issue 1/2007
Electronic ISSN: 1477-7525
DOI
https://doi.org/10.1186/1477-7525-5-47

Other articles of this Issue 1/2007

Health and Quality of Life Outcomes 1/2007 Go to the issue